BW

p53 (G372) polyclonal Antibody | BS3155

(No reviews yet) Write a Review
SKU:
BW-BS3155
Availability:
Usually ships in 5 working days
£732.00 - £1,098.00

Description

p53 (G372) polyclonal Antibody | BS3155 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: IHC

Application Range: IHC: 1:50~1:200

Background: p53, a DNA-binding, oligomerization domain and transcription activation domain-containing tumor suppressor, upregulates growth arrest and apoptosisrelated genes in response to stress signals, thereby influencing programmed cell death, cell differentiation and cell cycle control mechanisms. p53 localizes to the nucleus, yet can be chaperoned to the cytoplasm by the negative regulator MDM2, an E3 ubiquitin ligase that is upregulated in the presence of active p53, where MDM2 poly-ubiquitinates p53 for proteasome targeting. p53 fluctuates between latent and active (DNA-binding) conformations and is differentially activated through posttranslational modifications including phosphorylation and acetylation.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p53 (G372) polyclonal Antibody detects endogenous levels of p53 protein.

Molecular Weight: ~53,43 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Cellular tumor antigen p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53; TP53; P53

Immunogen: Synthetic peptide, corresponding to amino acids 341-390 of Human p53.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Regulation of Apoptosis,Hypoxia Signaling,Warburg Effect,Signaling Pathways Activating p38 MAP KinaseCell Cycle Control G1 S Checkpoint,Examples of Crosstalk Between Post-translational Modifications,Cell Cycle G2 M DNA Damage Signaling Pathway,

View AllClose